ATOS Atossa Therapeutics, Inc.
USHealthcareAs of 2026-07-09 11:38
Why ATOS matters now
Atossa Therapeutics, Inc. (ATOS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.30 with -6.12% on the session and $19.8M in market capitalization; recent performance reads 1-month -57.68% and YTD -77.29%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-9.6M, and EPS of $-1.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -193.0%.
The latest indexable market news headline is "Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Cigler Tessa filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.57
P/S
0.00
EV/EBITDA
0.38
DCF Value
$4.34
FCF Yield
-193.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-84.9%
ROA
-99.2%
ROIC
-129.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-9.6M | $-1.11 |
| Q4 2025 | $0.00 | $-10.9M | $-1.27 |
| FY 2025 | $0.00 | $-34.8M | $-4.04 |
| Q3 2025 | $0.00 | $-8.7M | $-1.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.